As of 2026-10-07, the Intrinsic Value of Viracta Therapeutics Inc (VIRX) is -43.18 USD. This VIRX valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.08 USD, the upside of Viracta Therapeutics Inc is -55,598.78%.
Based on its market price of 0.08 USD and our intrinsic valuation, Viracta Therapeutics Inc (VIRX) is overvalued by 55,598.78%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -43.18 - -43.18 | -43.18 | -55,598.78% |
| P/E | (215.03) - (215.89) | (220.86) | -283976.1% |
| DDM - Stable | (26.53) - (177,567.55) | (88,796.99) | -114135050.8% |
| DDM - Multi | (24.93) - (170,284.94) | (55.93) | -71991.3% |
| Market Cap (mil) | 0.39 |
| Beta | -1.17 |
| Outstanding shares (mil) | 5.01 |
| Enterprise Value (mil) | 4.17 |
| Market risk premium | 4.60% |
| Cost of Equity | 14.40% |
| Cost of Debt | 5.00% |
| WACC | 3.83% |